OIP106 CRISPR/Cas9 KO Plasmid (h): sc-406170
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- OIP106 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the OIP106 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
OIP106 CRISPR/Cas9 KO Plasmid (h) | sc-406170 | 20 µg | $397.00 |
Overview
TRAK1 encodes OIP106, a cytoplasmic adaptor implicated in organizing intracellular transport by linking cargo to microtubule-based motor complexes. OIP106 has been associated with mitochondrial trafficking and positioning, processes that influence neuronal polarity, axonal transport, and cellular bioenergetics. Through these roles, TRAK1 is studied in pathways governing organelle dynamics, cytoskeletal organization, and stress responses that shape cell survival and differentiation. Dysregulation of organelle transport and mitochondrial distribution is relevant to research on neurodevelopmental and neurodegenerative disease mechanisms and other disorders with altered cellular energetics.
OIP106 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TRAK1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TRAK1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TRAK1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish OIP106 protein expression.
This CRISPR knockout system enables efficient generation of TRAK1-deficient cell models for investigation of OIP106 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TRAK1 exon(s) critical for OIP106 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TRAK1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by OIP106 CRISPR/Cas9 KO Plasmid (h) and OIP106 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TRAK1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by OIP106 HDR Plasmid (h) and OIP106 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TRAK1 homology arms to support homology-directed repair at defined TRAK1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.